Literature DB >> 1757474

Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.

C L Tendler1, S J Greenberg, J D Burton, D Danielpour, S J Kim, W A Blattner, A Manns, T A Waldmann.   

Abstract

The human T-cell lymphotropic virus type I (HTLV-I) is capable of inducing a variety of host cellular genes including many of the cytokines responsible for immune regulation and osteoclast activation. This derangement in cytokine expression may contribute to the panoply of disease states associated with HTLV-I infection such as the adult T-cell leukemia (ATL) and HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). We wished to determine if there was a correlation between the expression of an array of cytokines and the diverse clinical manifestations of ATL and HAM/TSP. Utilizing the techniques of specific mRNA amplification by the polymerase chain reaction (PCR) as well as Northern blotting, we analyzed the ex vivo mRNA expression of gamma-interferon (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and transforming growth factor-beta 1 (TGF-beta 1) in the peripheral blood of HAM/TSP and ATL patients as well as asymptomatic seropositive carriers. IFN-gamma, TNF-alpha, and IL-1 beta transcripts were up-regulated in patients with HAM/TSP and seropositive carriers when compared to their levels in ATL and normal controls. In contrast, the ATL patients constitutively expressed higher levels of TGF-beta 1 mRNA than HAM/TSP and seropositive carriers. In addition, TNF-alpha and IL-1 beta serum levels were elevated in HAM/TSP, but not in ATL patients nor seropositive carriers. However, the circulating leukemic cells from ATL patients secreted increased levels of TGF-beta 1 protein into the culture medium than T-cells derived from HAM/TSP patients. Collectively these results suggest that induction of IFN-gamma, TNF-alpha, and IL-1 beta in HAM/TSP may initiate an inflammatory cascade with subsequent events leading to immune mediated destruction of the central nervous system in these patients. Expression of osteoclast activators such as TNF-alpha and IL-1 beta is not associated with hypercalcemia in ATL. Finally, impaired cellular and humoral immune responses present in ATL, but not in HAM/TSP, may be related to elevated levels of TGF-beta 1 produced by the leukemic cells. These differences in retroviral-induced host cytokine expression in ATL and HAM/TSP suggest alternate roles in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757474     DOI: 10.1002/jcb.240460405

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  30 in total

1.  Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of individuals infected with human T lymphotropic virus type-1 (HTLV-1).

Authors:  M Seki; J I Kadota; Y Higashiyama; K Iida; T Iwashita; E Sasaki; S Maesaki; K Tomono; S Kohno
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Induction of the POU domain transcription factor Oct-2 during T-cell activation by cognate antigen.

Authors:  S M Kang; W Tsang; S Doll; P Scherle; H S Ko; A C Tran; M J Lenardo; L M Staudt
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

3.  Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site.

Authors:  N Azimi; K Brown; R N Bamford; Y Tagaya; U Siebenlist; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  Soluble factors, including TNF alpha, secreted by human T cells are both cytotoxic and cytostatic for medulloblastoma cells.

Authors:  N Dufay; A Reboul; F Touraine-Moulin; M F Belin; P Giraudon
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

5.  Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation.

Authors:  R N Bamford; A P Battiata; J D Burton; H Sharma; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  Up-regulation of human T lymphotropic virus type 1 (HTLV-1) tax/rex mRNA in infected lung tissues.

Authors:  M Seki; Y Higashiyama; A Mizokami; J Kadota; R Moriuchi; S Kohno; Y Suzuki; K Takahashi; T Gojobori; S Katamine
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

7.  Stimulation of alpha 1 (I) procollagen gene expression in NIH-3T3 cells by the human T cell leukemia virus type 1 (HTLV-1) Tax gene.

Authors:  E Muñoz; D Suri; S Amini; K Khalili; S A Jiménez
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  J D Burton; R N Bamford; C Peters; A J Grant; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  R N Bamford; A J Grant; J D Burton; C Peters; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.